Affiliation:
1. Cell signaling Unit, Division of Experimental Oncology IRCCS San Raffaele Scientific Institute Milano Italy
2. Center for Omics Sciences IRCCS San Raffaele Scientific Institute Milano Italy
3. B‐cell neoplasia Unit Division of Experimental Oncology IRCCS San Raffaele Scientific Institute Milano Italy
4. Vita‐Salute San Raffaele University Milano Italy
Abstract
AbstractChronic lymphocytic leukemia (CLL) co‐evolves with its own microenvironment where inflammatory stimuli including toll‐like receptors (TLR) signaling can protect CLL cells from spontaneous and drug‐induced apoptosis by upregulating IκBζ, an atypical co‐transcription factor. To dissect IκBζ‐centered signaling pathways, we performed a gene expression profile of primary leukemic cells expressing either high or low levels of IκBζ after stimulation, highlighting that IκBζ is not only an inflammatory gene but it may control metabolic rewiring of malignant cells thus pointing to a novel potential opportunity for therapy. We exploited the capacity of the dimethyl itaconate (DI), an anti‐inflammatory electrophilic synthetic derivative of the metabolite Itaconate, to target IκBζ. CLL cells, murine leukemic splenocytes, and leukocytes from healthy donors were treated in vitro with DI that abolished metabolic activation and reduced cell viability of leukemic cells only, even in the presence of robust TLR prestimulation. RNA sequencing highlighted that in addition to the expected electrophilic stress signature observed after DI treatment, novel pathways emerged including the downregulation of distinct MHC class II complex genes. In conclusion, DI not only abrogated the proinflammatory effects of TLR stimulation but also targeted a specific metabolic vulnerability in CLL cells.
Subject
Immunology,Immunology and Allergy
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献